Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review
International Journal of Dermatology · 2024
DOI: 10.1111/ijd.17157 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Amelia Utama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Skin Centre, Singapore, Singapore. Hauptthemen laut MEDLINE: Vitiligo, Janus Kinase Inhibitors, Pyrimidines, Piperidines. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Vitiligo is a chronic skin condition caused by an autoimmune response that results in the progressive loss of melanocytes and recent studies have suggested that Janus kinase inhibitors (JAKi) are emerging as a promising new treatment modality. Therefore, to assess and understand the extent of knowledge in the emerging field of JAKi use in vitiligo, a scoping review of the literature was undertaken. The reviewed articles explored a wide variety of JAKi administered either orally or topically for vitiligo. There were no injectable JAKi studied. Tofacitinib was the most commonly studied oral JAKi in 16 of the 35 studies selected for review, followed by baricitinib ( n = 3), and one study each with ritlecitinib, ruxolitinib, and upadacitinib. Ruxolitinib ( n = 6) and tofacitinib ( n = 6) were the most often studied topical JAKi, followed by delgocitinib ( n = 1). Potential benefits may vary between JAKi based on their receptor selectivity profile and coexistent autoimmune diseases. A topical JAKi would be advantageous in limited body area involvement and in adolescents. Concurrent use of JAKi with phototherapy or sun exposure appears beneficial. Most studies permitted the use of other topical agents. Acne‐related events, though frequent yet mild, were reported with both oral and topical JAKi. Nasopharyngitis, upper respiratory tract infections, and headaches were the most common adverse effects seen in the larger trials with JAKi. No serious or clinically meaningful hematology or thromboembolic events were detected. Treatment of vitiligo with oral or topical JAKi seems to be promising and the growing evidence shows a favorable risk‐benefit profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, National Skin Centre, Singapore, Singapore.
- Department of Dermatology, National Skin Centre, Singapore, Singapore.
ORCID-Profile: Amelia Utama, Ruki Wijesinghe, Steven Thng
Zitieren
APA
Utama, A., Wijesinghe, R., & Thng, S. (2024). Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. International Journal of Dermatology. https://doi.org/10.1111/ijd.17157
Vancouver
Utama A, Wijesinghe R, Thng S. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. International Journal of Dermatology. 2024. doi:10.1111/ijd.17157
BibTeX
@article{Utama2024,
author = {Utama, Amelia and Wijesinghe, Ruki and Thng, Steven},
title = {Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review},
journal = {International Journal of Dermatology},
year = {2024},
doi = {10.1111/ijd.17157}
}
EUVIMED